drugset / Trial / NCT04712942
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
RandomizedParallel-groupOpen-labelTreatment
Summary
MDS/AML with MRD and impending relapse after allogeneic stem cell transplantation and/or conventional chemotherapy
Timeline
- Start
- 2021-01-01
- Primary completion
- 2023-01-31
- Completion
- 2023-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Pevonedistat | Small molecule | 20 mg/m2 | Intravenous |